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Anticonvulsant drugs can cause various forms of skin drug reactions, ranging 
from exanthema to severe blistering reactions. An association between 
HLA-B*1502 allele and severe skin reactions have been reported.
Materials & Methods
Fifteen patients with severe skin reactions following treatment with 
anticonvulsant drugs (Carbamazepine, lamotrigine, phenobarbital, primidone) 
and 15 controls (age-matched epileptic patients taking similar anticonvulsants 
without drug eruption) were included. They were referred to Mofid Children’s 
Hospital in Tehran, Iran, between Jan 2012 to Jan 2014. Genomic DNA was 
extracted from peripheral blood of all patients and HLA- B*1502 genotype was 
detected by real-time PCR. 
Results
None of the patients was positive for HLA- B*1502, but two patients in control 
group had positive HLA- B*1502. 
Conclusion
The HLA- B*1502 is not correlated with severe anticonvulsant drugs -induced 
skin reactions in Iranian children.
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Introduction 
Epilepsy is one of the most common serious neurological disorders and the 
cornerstone of its treatment is usage of anti-epileptic drugs. A minority of patients 
under treatment with anticonvulsant drugs shows broad-spectrum skin reactions 
as an adverse effect. These reactions include Stevens–Johnson syndrome (SJS), 
toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic 
symptoms (DRESS), classified according to skin manifestations and percentage of 
body surface involved) 1, 2). Genomewide approach has been used to identify HLA 
alleles and genetic predisposing factors for drug-induced skin reactions (3). 
In some Asian and European countries, HLA- B*1502 and HLA-A*3101 has been 
identified as predictive genetic markers for carbamazepine hypersensitivity (4). 
Recent studies have shown an association between HLA-B*1502 and antiepileptic 
drug-induced cutaneous reactions, including carbamazepine, phenytoin, and 
lamotrigine (5, 6).
These reactions have high morbidity and can be lethal. Screening of children, who 
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skin drug reactions due to anticonvulsant therapy 
were included in this study. All of the patients were 
under treatment with aromatic cyclic anticonvulsants 
(Phenobarbital, lamotrigine, carbamazepine, and 
primidone) and had shown one of the severe skin drug 
reactions. The mean and standard deviation of age at 
presentation were 4.24±2.52 years. The youngest patient 
was 8 months old and the oldest was 8 years old. The 
average time interval between drug consumption and 
drug reaction was 14.87±5.85 days. Eight patients had 
an abnormal EEG; one was mental retard; seven patients 
had respiratory or gastrointestinal allergies or positive 
family history of allergy.
Skin drug reactions were seen in 8 patients following 
phenobarbital consumption, in 5 patients for 
carbamazepine, in 1 patient for primidone, and 1 patient 
for lamotrigine. Skin drug reactions were seen in 6 
patients as Stevens-Johnson syndrome, in 5 patients 
as toxic epidermal necrolysis, in one case as overlap 
syndrome and in 3 patients as DRESS. The number of 
different reactions following consumption of each drug 
is summarized in Table 1.
At the time of skin involvement, 10 patients were febrile 
and 4 patients had lymphadenopathy. Four patients 
had simple febrile convulsion, 2 had complex febrile 
convulsion (recurrent seizures, twice in one patient 
and three times in another patient) and 2 patients had 
one afebrile seizure (with normal neurodevelopment).
Anticonvulsant drugs was discontinued in these patients 
after skin drug reaction. Seven other patients had recurrent 
seizures with necessity to continue anticonvulsant drugs.
The average dose of drug consumption in patients with 
skin reaction was 5mg/kg for phenobarbital and 13 
mg/kg for carbamazepine. Brain MRI was done in 10 
patients, reported abnormal in 2 of them (Brain atrophy 
was reported in one patient and in another one cystic 
encephalopathy was detected due to hypoxic-ischemic 
encephalopathy at birth)
The HLA- B*1502 allele was tested in all of the patients 
in case and control groups. This test was negative in all 
patients in case group, but two patients in control group 
were positive for HLA- B*1502.
Discussion
Anticonvulsant drugs are a group of pharmacological 
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are genetically vulnerable to these skin reactions, can 
help us to prevent these complications. As there is no 
data about the relationship of HLA- B*1502 and severe 
drug reactions to anti-epileptic drugs in Iranian children, 
we designed this study to elucidate the importance of 
HLA- B*1502 in adverse reactions. 
Materials & Methods
This cross-sectional descriptive study was performed 
on 15 patients, referred to Mofid Children’s Hospital in 
Tehran, Iran, between Jan 2012 to Jan 2014, with severe 
skin reactions (SJS,TEN, overlap syndrome and DRESS) 
after anticonvulsant drug consumption (Carbamazepine, 
lamotrigine, phenobarbital, primidone) and compared to 
15 patients with seizure disorders, treated with similar 
anticonvulsant drugs for at least 3 months and had not 
shown any adverse reaction (control group). The case 
and control groups were age and sex matched. 
The patients’ data were recorded in a questionnaire 
including age, gender, type of reaction, type of the 
anti-epileptic drug used, dosage and duration of drug 
consumption, history of gastrointestinal and respiratory 
hypersensitivities, concomitant symptoms such as fever 
and lymphadenopathy, type of seizure including EEG 
findings, Brain MRI and laboratory findings (CBC, diff, 
eosinophilia, ESR, AST, ALT). A clinical immunologist-
allergist, based on skin reaction criteria (7), confirmed 
diagnosis of the type of skin reaction.
After signing an informed consent by the patients’ 
parents, 3 mL EDTA blood was taken from patients in 
case and control groups. The study was approved by 
Ethics Committee of the hospital.
Genomic DNA was extracted from peripheral blood of 
all patients and control groups, using QIMamp DNA 
mini kit (Qiagen, US), according to the manufacturer’s 
instruction.
HLA- B*1502 genotype was detected by real-time PCR 
(RT-PCR). For this purpose, PG 1502 DNA detection 
kit (Pharmigene Inc., Taipei City, Taiwan) was used. 
Amplification and detection was done according to 
the manufacturer’s instruction for applied Biosystems 
stepone plus.
Results
Fifteen patients (11 males and 4 females) with severe 
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lamotrigine (5, 6).
We did not find any association between HLA-B*1502 
and antiepileptic drug-induced cutaneous reactions to 
carbamazepine, lamotrigine, phenobarbital, primidone.
Because of high incidence of HLA-B*1502 in many 
Asian populations, FDA has recommended HLA-B*1502 
testing for all Asians before starting carbamazepine 
treatment (18). Although FDA has recommended 
HLA-B*1502 testing before using carbamazepine, no 
association between HLA- B*1502 and severe skin drug 
reactions was seen in this study. HLA- B*1502 testing 
before anticonvulsant consumption is not helpful in the 
Iranian population. 
In conclusion, no association between HLA- B*1502 
and severe skin reactions due to aromatic anticonvulsant 
drug consumption was noticed. Besides, HLA- B*1502 
testing may not be helpful in prediction of severe skin 
reactions in Iranian population. However, another study 
with more samples is required to conclude precisely.
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agents used in the treatment of seizures. Some 
patients develop hypersensitivity reactions following 
administration of these drugs (1, 2). A strong relationship 
between anticonvulsant drugs induced skin reactions 
and certain HLA alleles has been reported (4, 5).
Many studies have emphasized the association between 
antiepileptic drug consumption and skin reactions (8-
12). In our study, all of the patients have shown severe 
skin drug reactions due to aromatic anticonvulsant drugs 
consumption and most of the reactions were reported 
due to phenobarbital consumption. Phenobarbital is used 
more than other anticonvulsant drugs in our country. 
The average dose of drug consumption in patients with 
skin reaction was 5 mg/kg for phenobarbital and 13 mg/
kg for carbamazepine. These doses are not considered as 
a high level and these reactions are idiosyncratic.
A strong association were demonstrated between 
HLA-B*1502 and carbamazepine-induced SJS in Asian 
areas including Taiwan, Hongkong, and Thailand (11).
The association between carbamazepine-induced side 
effect and HLA-B*1502 allele were reported in Han 
Chinese of southern China. The HLA-B*1502 allele 
frequency in patients with SJS/TEN was significantly 
higher than controls and HLA-B*1502 allele had 45% 
positive predictive value, 100% sensitivity, 86.25% 
specificity and 100% negative predictive value for 
prediction of skin reactions(9). 
HLA-B*1502 allele was seen in all of the patients with 
SJS due to Carbamazepine usage, but in 9% of the control 
population (13). The association between HLAB*1502 
and carbamazepine-induced SJS/TEN was confirmed 
in Han Chinese and Thai populations(14, 15), but this 
association was not confirmed in Japan (16).
Studies in Caucasians patients have reported no 
association between carbamazepine-induced SJS and 
HLA-B*1502, thus HLA-B*1502 allele did not exist in 
all ethnicities (17).
Some studies have implicated that there is an association 
between the HLA B*1502 as a marker for carbamazepine-
induced SJS and TEN in Han Chinese, but there is no 
published data to show the association of HLA-B*1502 
and carbamazepine-induced SJS and TEN in non-
Chinese Asians. An association was shown between 
HLA-B*1502 and cutaneous reactions following 
usage of other antiepileptic drugs like phenytoin, and 
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